超顺磁性氧化铁增强0.35T磁共振引导放疗在肝脏恶性肿瘤中的应用:肿瘤可视化的价值
本研究回顾性纳入42例接受0.35T磁共振引导立体定向消融放疗的肝脏肿瘤患者,比较超顺磁性氧化铁给药前后真稳态进动快速成像上的肿瘤-肝脏信号比。给药前15例(36%)肿瘤不可见或勉强可见,给药后所有肿瘤均可见;平均信号比由0.939±0.201升至1.336±0.300(P<0.001);但6例(14%)给药前可见的肿瘤在给药后变为不可见。
要点
- 0.35T磁共振引导放疗中,超顺磁性氧化铁可使真稳态进动快速成像上原本不可见的肝脏肿瘤变为可见。
- 给药后肿瘤-肝脏信号比平均值由0.939±0.201升至1.336±0.300(P<0.001)。
- 需注意14%(6例)患者给药前可见的肿瘤在给药后反而变为不可见。
核心结论
- 真稳态进动快速成像上不可见的肝脏肿瘤可通过给予超顺磁性氧化铁变为可见,从而可准确实施磁共振引导立体定向消融放疗。
研究设计与样本
- 回顾性研究,纳入42例接受磁共振引导立体定向消融放疗的肝脏肿瘤患者,在0.35T磁共振引导放疗系统上于超顺磁性氧化铁给药前后行真稳态进动快速成像并比较肿瘤-肝脏信号比。
关键影像表现/征象
- 超顺磁性氧化铁给药前,15例(36%)肝脏肿瘤在真稳态进动快速成像上不可见或勉强可见,给药后所有肿瘤均变为可见。
- 6例(14%)患者给药前真稳态进动快速成像上可见的肝脏肿瘤,在给药后变为不可见。
诊断标准与关键数值
- 超顺磁性氧化铁给药前后肿瘤-肝脏信号比平均值分别为0.939±0.201和1.336±0.300(均值±标准差,P<0.001)。
临床应用与阅片要点
- 在0.35T磁共振引导放疗的真稳态进动快速成像上,对给药前不可见或勉强可见的肝脏肿瘤,给予超顺磁性氧化铁后有助于肿瘤显示。
- 对给药前已可见的肝脏肿瘤,需注意给药后可能变为不可见(本组6例,14%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The purpose of this study was to investigate the changes of tumor-to-liver signal ratio in a 0.35T MRI-guided radiotherapy system and to evaluate the usefulness and pitfalls of superparamagnetic iron oxide (SPIO) administration for visualization of liver tumors.
METHODS: Forty-two patients treated with MRI-guided stereotactic ablative radiotherapy (SABR) for liver tumors were included in this study. The tumor-to-liver signal ratios before and after SPIO administration were retrospectively assessed and compared on true fast imaging with steady-state precession (FISP).
RESULTS: Before SPIO administration, liver tumors were either invisible or barely visible in 15 cases (36%), but all tumors became visible after SPIO administration. The mean values of tumor-to-liver signal ratio before and after SPIO administration were 0.939 ± 0.201 and 1.336 ± 0.300, respectively (mean ± standard deviation, p < 0.001). In six (14%) patients, liver tumors were visible on true FISP imaging before SPIO administration, but became invisible after administration.
CONCLUSIONS: This study showed that liver tumors that are invisible on true FISP imaging can be made visible by administration of SPIO, and that MRI-guided SABR can be performed accurately.
ADVANCES IN KNOWLEDGE: This is the first report to examine the usefulness of liver-specific contrast agent superparamagnetic iron oxides in 0.35T MRI-guided radiation therapy. Liver tumors that are invisible on true fast imaging with steady-state precession can be made visible by administration of superparamagnetic iron oxides.
引用
- Hama, Tate. SPIO-enhanced 0.35T MRI-guided radiotherapy for liver malignancies: usefulness in tumor visualization. Br J Radiol. 2022. PMID: 35333542. doi:10.1259/bjr.20211131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。